Key Findings:  Approximately 30-40% of adolescents and young adults with IBD will try cannabis and some report benefit for their IBD. There is some rationale for considering a possible immune modifying effect of cannabis on IBD. The possible benefits and significant risks need to be better understood. However, the current regulatory environment imposes unique challenges on performing rigorous research into cannabis use. Care providers should become familiar with the issues around cannabis use and maintain open communication with their pediatric IBD patients.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  United States
Year of Pub:  2018
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2, GPCR 55, TRPV1
Ligands Studied:  Anti-inflammatory cytokines, Pro-inflammatory cytokines